DaVita Inc. (NYSE:DVA) Shares Sold by Millennium Management LLC

Millennium Management LLC cut its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 28.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 124,483 shares of the company's stock after selling 50,560 shares during the quarter. Millennium Management LLC owned about 0.15% of DaVita worth $18,616,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DVA. Wellington Management Group LLP raised its stake in shares of DaVita by 9.1% in the fourth quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock worth $405,000 after purchasing an additional 227 shares during the last quarter. Hussman Strategic Advisors Inc. raised its stake in shares of DaVita by 200.0% in the fourth quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company's stock worth $3,769,000 after purchasing an additional 16,800 shares during the last quarter. Caprock Group LLC purchased a new position in shares of DaVita in the fourth quarter worth about $200,000. Yousif Capital Management LLC raised its stake in shares of DaVita by 22.1% in the fourth quarter. Yousif Capital Management LLC now owns 10,362 shares of the company's stock worth $1,550,000 after purchasing an additional 1,877 shares during the last quarter. Finally, Convergence Investment Partners LLC raised its stake in shares of DaVita by 33.2% in the fourth quarter. Convergence Investment Partners LLC now owns 11,389 shares of the company's stock worth $1,703,000 after purchasing an additional 2,836 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

DaVita stock traded up $1.63 during midday trading on Tuesday, hitting $139.82. 794,960 shares of the company were exchanged, compared to its average volume of 826,146. The firm has a market capitalization of $10.56 billion, a PE ratio of 13.02, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. DaVita Inc. has a fifty-two week low of $131.76 and a fifty-two week high of $179.60. The business has a fifty day simple moving average of $144.90 and a two-hundred day simple moving average of $153.24. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. During the same period last year, the company earned $2.26 earnings per share. DaVita's quarterly revenue was up 5.0% compared to the same quarter last year. On average, sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Barclays raised their price objective on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Truist Financial reduced their price objective on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. Finally, Cowen reaffirmed a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $164.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.